Abstract
Background and Objectives Times to clinically relevant events are a valuable outcome in observational and interventional studies, complementing linear outcomes such as functional rating scales and biomarkers. In ALS, there are several clinically relevant events. We developed dynamic prediction models for several of these times to events that can be used for clinical trial modeling and personal planning.
Methods Landmark time-to-event analysis was implemented to determine the effect of patient characteristics on disease progression. Longitudinal data from 1557 participants in the ALS Natural History Consortium dataset were used. Five outcomes in the ALS disease progression were considered: loss of ambulation, loss of speech, gastrostomy, non-invasive ventilation (NIV) use, and continuous NIV use. Covariates in our models include age at diagnosis, sex, onset location, riluzole use, diagnostic delay, ALSFRS-R scores at the landmark time, and ALSFRS-R rates of change from baseline. Internal and external validation techniques were used.
Results For each of our models and landmark times, we present risk prediction intervals for random sets of patient characteristics. We demonstrate our models’ application for an individual’s personal predicted time-to-event. Our internal and external validation metrics indicate good concordance and overall performance. The time to loss of speech models perform the best for each metric in terms of both internal and external validation.
Discussion Landmarking is an efficient, individualized risk prediction model that is intuitive for both clinicians and patients. Importantly, landmarking can be used for clinical trial modeling, personal planning, and development of real-world evidence of the impacts of treatment interventions.
Competing Interest Statement
XAL reports the Trial Capacity Award Recipient 2022, ALS Association Grant; CL received compensation for scientific consulting from Mitsubishi Tanabe Pharma Europe and Biogen, his research has been funded by grants from ALSA, ARISLA, the Italian Ministry of Health, and the Italian Ministry of Research, his work has been partially supported by the Italian Ministry of Health's RC program; JW reports MT Pharma for grant support; KG has received consulting honoraria from Alexion, Argenx, Amgen and UCB, remotely received speaking honoraria from Argenx and Alexion; SAD reports research support from Biogen, Amylyx pharmaceuticals, Mitsubishi Tanabe Pharma America, Alnylam, Novartis, Sanofi, reports personal consulting fees from Biogen and Amylyx pharmaceuticals, served as a paid educational presenter for Biogen; GH reports support from Speaking Bureau, Alexion, Argenx, MTPA; THP reports support from Medical Advisory Board for Mitsubishi Tanabe Pharma America, Amylyx, Novartis, Clinical trial funding: Amylyx, Novartis, Mitsubishi Tanabe Pharma, Healey Platform Trial, Clinical Research Funding: Amylyx, Mitsubishi Tanabe Pharma America; CNF reports consulting fees from Novartis, Roon, and QurALIS; JDG reports funding from NINDS and NIA, Consulting for Biogen, NuraBio, Aruna Bio, Third Rock; AS has received grants and contracts for clinical research projects sponsored by FDA, NIH/NIA, NIH/NINDS, The ALS Association, and ALS Finding a Cure Foundation as well as study support from MTPA, Biogen, and Amylyx; DW reports grant support from FDA's Office of Orphan Products Development and consulting fees from Biogen, Mitsubishi Tanabe Pharma America, and Amylyx. All other authors have no relevant disclosures to report.
Funding Statement
This project was supported by the FDAs Office of Orphan Products Development under grant number FD-R01-0007630. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the FDA nor FDAs Office of Orphan Products Development.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants provided written informed consent to be included in the database. Current IRB numbers: University of Minnesota (UMN) sIRB: 00019204; Istituti Clinici Scientifici Maugeri: 2687CE; and Centro Clinico NeMO: 247-052017. Prior IRB numbers: UMN: 1501M61381; Northwestern: STU00209860; Saint Louis University: 28018; Temple: 25661; Virginia Commonwealth University: HM20009645; University of Florida: IRB201701910; Henry Ford: 10105; and Providence: 16-123A. Data from Emory University collected through the Clinical Research in ALS Study (CRiALS), IRB: 00078771.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data are available upon reasonable request for research purposes. If interested please reach out to the senior author Dr. David Walk (walkx001{at}umn.edu) for further instructions and availability questions.
